Novo nordisk a/s: new data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials

BagsvÆrd, denmark, sunday 25 june 2023 – novo nordisk today announced data from the phase 3a onwards 1 and 3 trials evaluating investigative once-weekly basal insulin icodec, which were presented at the 83rd annual scientific sessions of the american diabetes association (ada). the data showed the studies met their primary endpoints, while reducing injections from seven to one per week, compared with once-daily basal insulin1,2. additionally, data from the onwards 1 and 3 studies demonstrated that more insulin-naÏve adults with type 2 diabetes treated with once-weekly basal insulin icodec achieved an hba1c target of
NVO Ratings Summary
NVO Quant Ranking